Zymeworks is a clinical-stage biopharmaceutical company focused on the development of multifunctional biotherapeutics. Co.'s primary product candidate, zanidatamab, is a bispecific (dual-targeting) antibody that targets two domains of the human epidermal growth factor receptor 2. Co.'s second product candidate, ZW49, combines the design of zanidatamab with its ZymeLink antibody-drug conjugate platform, comprised of its proprietary cytotoxin (cancer cell-killing compound) and cleavable linker. Co. is also developing a pipeline of preclinical product candidates and discovery-stage programs in oncology (including immuno-oncology agents) and other therapeutic areas. The ZYME YTD return is shown above.
The YTD Return on the ZYME YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ZYME YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ZYME YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|